title: Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
abstract: Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant prostate cancer who have progressive disease after first-line chemotherapy treatment. In addition, it is currently being tested in a Phase III trial in the pre-chemotherapy setting. This paper will review the preclinical discovery and clinical development of AA and will outline the strategy of parallel translational research.
authors.affiliation: Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
authors.forename: Carmel J
authors.initials: CJ
authors.lastname: Pezaro
authors.forename: Deborah
authors.initials: D
authors.lastname: Mukherji
authors.forename: Johann S
authors.initials: JS
authors.lastname: De Bono
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000730:Androstadienes / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D000730:Androstadienes; D000069501:Abiraterone Acetate